
==== Front
iScience
iScience
iScience
2589-0042
Elsevier

S2589-0042(24)01951-5
10.1016/j.isci.2024.110726
110726
Review
Protective role of acetylcholine and the cholinergic system in the injured heart
Liu Chung Ming Clara 12
Wang Xiaowei xiaowei.wang@baker.edu.au
345∗
Gentile Carmine carmine.gentile@uts.edu.au
12∗∗
1 School of Biomedical Engineering, Faculty of Engineering and Information Technology, University of Technology Sydney, Sydney, NSW, Australia
2 Cardiovascular Regeneration Group, Heart Research Institute, Newtown, NSW 2042, Australia
3 Department of Medicine, Monash University, Melbourne, VIC 3800, Australia
4 Department of Cardiometabolic Health, University of Melbourne, Melbourne, VIC 3010, Australia
5 Molecular Imaging and Theranostics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia.
∗ Corresponding author xiaowei.wang@baker.edu.au
∗∗ Corresponding author carmine.gentile@uts.edu.au
14 8 2024
20 9 2024
14 8 2024
27 9 110726© 2024 The Author(s)
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Summary

This review explores the roles of the cholinergic system in the heart, comprising the neuronal and non-neuronal cholinergic systems. Both systems are essential for maintaining cardiac homeostasis by regulating the release of acetylcholine (ACh). A reduction in ACh release is associated with the early onset of cardiovascular diseases (CVDs), and increasing evidence supports the protective roles of ACh against CVD. We address the challenges and limitations of current strategies to elevate ACh levels, including vagus nerve stimulation and pharmacological interventions such as cholinesterase inhibitors. Additionally, we introduce alternative strategies to increase ACh in the heart, such as stem cell therapy, gene therapy, microRNAs, and nanoparticle drug delivery methods. These findings offer new insights into advanced treatments for regenerating the injured human heart.

Graphical abstract

Cardiovascular medicine; Pathophysiology

Subject areas

Cardiovascular medicine
Pathophysiology
==== Body
pmcIntroduction

Cardiovascular diseases (CVDs) are a leading contributor to global mortality and morbidity, responsible for an estimated 17.9 million deaths each year, as reported by the World Health Organization.1 In the early phases of CVD, an imbalance occurs within the autonomic system, marked by an increase in sympathetic activity and a decrease in the parasympathetic system. This disequilibrium is associated with an increase in norepinephrine and a reduction in the release of acetylcholine (ACh), contributing to higher rates of cardiac mortality and hindering myocardial regeneration.2,3,4 Early studies reported that an increase in sympathetic activation and parasympathetic inhibition in dogs leads to tachycardia-induced heart failure (HF) .5 Additionally, Mahmoud et al.2 demonstrated that inhibition of the cholinergic nerve during cardiac injury in neonatal mice and zebrafish leads to incomplete heart regeneration, causing a significant decrease in neonatal cardiac cell proliferation. In clinical trials, such as the Autonomic Tone and Reflexes After Myocardial Infarction study and Cardiac Insufficiency Bisoprolol Study II, reduced cardiac vagal activity is associated with increased heart rate and higher mortality rates in HF patients.6,7 In pre-clinical studies, Guimarães8 demonstrated that mice with a long-term cholinergic deficit exhibit increased norepinephrine levels and heightened sympathetic activity, resulting in cardiotoxicity. However, the correlation between CVD and autonomic dysfunction is still not well understood.

Several studies have reported that a decrease in ACh release, stemming from reduced cholinergic activity, is linked with various CVDs, including arrhythmias,9 atherosclerosis,10,11 myocardial infarction (MI),12,13 ischemic-reperfusion injury (I/R),14,15 doxorubicin (DOX)-induced cardiotoxicity,16 and HF.17 Additionally, increasing ACh secretion restores the imbalance of the autonomic system, improves heart rate viability, regulates mitochondrial function, suppresses reactive oxygen species (ROS) production, and alleviates inflammatory responses.8,18 Several studies have shown that the cholinergic system in the heart plays a pivotal role in guiding cardiac regeneration in the injured heart in mice, rats, rabbits, swine, and canine.19,20,21,22,23 Nonetheless, these pre-clinical findings have not been successfully translated to clinical studies, potentially due to the variability in ACh delivery methods across studies and, more broadly, to the multitarget effects of ACh in the human body. Therefore, a better understanding of the potential protective roles of ACh against myocardial injury, as well as the mechanisms regulating this process, will facilitate the development of new therapeutic targets against cardiac damage.

In this review, we focus on both the neuronal and cardiomyocyte cholinergic systems in the heart. Both systems are interconnected and essential for regulating the release of ACh, which binds to muscarinic and/or nicotinic ACh receptors to activate various signaling pathways, thereby maintaining cardiac homeostasis. We discuss the role of ACh derived from both systems in the heart and its therapeutic potential through muscarinic and/or nicotinic ACh receptors against CVD. The review also examines the limitations and constraints of current methods used to increase ACh levels in pre-clinical and clinical trials, such as vagus nerve stimulation (VNS) and cholinesterase inhibitors. Finally, we highlight alternative approaches to target the cholinergic system for more targeted and less invasive therapeutic strategies.

The cholinergic system of the heart

The autonomic system is composed of the sympathetic and parasympathetic nervous systems, which work in opposition to each other to balance heart activity. The parasympathetic nervous system, also known as the neuronal cholinergic system, encompasses molecules responsible for the synthesis, storage, release, signaling, and degradation of ACh, collectively regulating extracellular ACh concentrations within the presynaptic terminal.18 As a neurotransmitter, ACh is employed to modulate cardiac activity through muscarinic ACh receptors (mAChRs) to regulate heart dynamics8 and through nicotinic ACh receptors (nAChRs) to modulate inflammatory pathways and cardiac hemodynamic.24

As outlined in Figure 1, ACh synthesis is catalyzed by choline acetyltransferase (ChAT), leading to its release and subsequent action in the cardiac extracellular space. The latter combines choline, supplied by a high-affinity choline transporter (CHT1), with acetyl-coenzyme A (CoA).18,25 ACh is stored within synaptic vesicles, which are acidified via an energy-dependent pump (H-ATPase) and mediated via vesicular ACh transporter (VAChT).26 Upon depolarization, calcium influx triggers exocytosis, wherein ACh-filled synaptic vesicles fuse with the cellular membrane, releasing ACh in the synaptic cleft.4 Once released into the extracellular space, neuronal-derived ACh binds to mAChRs and nAChRs to activate various signaling pathways in the cardiovascular system.27,28,29 The degradation of ACh occurs rapidly by cholinesterases, including acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Both AChE and BChE hydrolyze ACh into choline and acetate.30 CHT1 then transports choline to the presynaptic terminal.4,31Figure 1 Schematic illustration of the cardiac neuronal cholinergic system in both cardiomyocytes and cholinergic nerves

Acetylcholine (ACh) (red) derived from the presynaptic terminal and ACh (orange) derived from cardiomyocytes are synthesized by choline acetyltransferase (ChAT) from the reaction between acetyl-CoA and choline. ACh from the neuronal and non-neuronal cholinergic system is stored by the vesicular acetylcholine transporter (VAChT) and released upon stimulation. ACh released from both systems binds to ligand-gated ion channels nicotinic or G protein-coupled muscarinic ACh receptors (nAChRs and mAChRs, respectively). Acetylcholinesterase (AChE) present on postsynaptic terminal and cardiomyocytes and butyrylcholinesterase (BChE) present in the extracellular space degrade ACh to choline and acetate. High-affinity choline transporters (CHT1), present in cholinergic neurons and cardiomyocytes, are responsible for the reuptake of free choline for ACh synthesis.

Over the past two decades, a few studies have supported an additional intrinsic cholinergic machinery in heart cells, also known as the non-neuronal cholinergic system (NNCS) (which includes cardiomyocytes,14 endothelial cells,32 and leukocytes32,33). Recently, Tarnawski et al.32 showed that ACh-derived T cells regulate vascular endothelial function and blood pressure via promoting endothelial nitric oxide synthase activity, vasorelaxation, and reducing vascular endothelial activation. Although leukocytes and endothelial cells have been shown to have the components of cholinergic machinery, their contribution to the total pool of ACh in the heart is low and remains unexplored.4,34

In this review, we also focus on cardiomyocyte cholinergic machinery and the role played by cardiomyocyte-derived ACh in the heart. Cardiomyocytes can synthesize, transport, and release ACh, as they contain enzymes and transporters for ACh synthesis (ChAT), storage (VAChT), degradation (AChE and BChE), and reuptake of choline for synthesis (CHT1) (Figure 1).35,36 Roy et al.37 suggested that cardiomyocyte-derived ACh functions through similar second messenger systems and binds to mAChRs or nAChRs similar to neuronal-derived ACh. Additionally, studies have found that cardiomyocyte-derived ACh was detected intracellularly and extracellularly using cholinesterase inhibitors such as donepezil, pyridostigmine, and physostigmine.35,36 Hence, the NNCS in cardiomyocytes comprises those components that regulate ACh homeostasis and act in an auto-/paracrine manner to mediate signaling.18 This concludes that both the neuronal cholinergic system and NNCS crosstalk with each other to mediate and regulate homeostasis heart activity.

The role of cardiomyocyte-derived ACh in the heart

While both the neuronal cholinergic system and NNCS operate concurrently to regulate cardiac homeostasis, cardiomyocyte-derived ACh plays a crucial role in the heart and offers protection against CVD. ACh derived from cardiac NNCS sustains or enhances neuronal cholinergic effects, regulates heart rate, counteracts hypertrophic signals, maintains action potential propagation, and regulates cardiac energy metabolism.26,35,37,38,39,40 For instance, Roy et al.40 found that lowering the levels of cardiomyocyte-derived ACh using ChAT and VAChT knockout mice models resulted in increased heart rate and cardiovascular dysfunction. This suggests that a reduction in cardiomyocyte-derived ACh levels could potentially cause long-term changes in heart function, including ventricular cardiomyocyte hypertrophy, cardiac remodeling, and an increase in ROS.40 Similar to neuronal-derived ACh, cardiomyocyte-derived ACh is crucial for maintaining cardiac homeostasis and regulating critical signaling pathways to maintain normal heart activity. Furthermore, Kakinuma et al.41 demonstrated that ChAT deletion in murine atrial myocardial cells increased oxygen consumption, mitochondrial activity, and reduction of ATP levels. As a result, cardiac NNCS plays a protective role in cardiomyocytes and the entire heart by maintaining physiological ATP levels and inhibiting oxygen consumption.42

NNCS is also crucial for maintaining the balance between parasympathetic and sympathetic heart innervation and could amplify the protective effects of the parasympathetic nervous system.4,43 Few studies have shown that cardiomyocyte-derived ACh could modulate the central nervous system via the afferent vagal nerve, initiating crosstalk with other organs such as the brain, liver, and others.44 Increasing cardiac NNCS signaling through a genetic approach and/or pyridostigmine, a cholinesterase inhibitor, leads to protective immunomodulatory effects, such as a reduction in CCL2/7 chemokines expression and a decrease of pro-inflammatory CCR2+ monocytes in the heart following cardiac injury.45 This supports the cardioprotective role of cardiomyocyte-derived ACh via the modulation of the innate immune system.

Despite the fact that cardiac NNCS could be a potential target for therapeutic intervention, the detailed mechanisms that trigger the release of cardiomyocyte-derived ACh are still unclear. While Rocha-Resende et al.26 proposed that adrenergic stimulation can induce cholinergic gene expression in cardiomyocytes, Roy et al.37 suggested that cardiomyocyte-derived ACh may be regulated by sympathetic activity and the intrinsic cholinergic machinery, to regulate heart rate after stress and exercise. However, further studies are needed to identify the factors that activate NNCS in cardiomyocytes.

The role of cardiomyocyte-derived ACh against CVD

In this sub-section, we explore the potential therapeutic role of targeting cardiac NNCS and the protective role of cardiomyocyte-derived ACh against CVD. The current methods to increase cardiac NNCS activity are cholinesterase inhibitors, including pyridostigmine26,45 and donepezil,35 small interfering RNA targeting AChE to increase ACh level,26 and overexpression of ChAT gene42,46 or VAChT gene.45 Numerous studies have demonstrated that cardiac NNCS reduces oxygen demand and improves oxygen supply during ischemic injury, thereby preventing ischemia-induced cardiac dysfunction42,45 as well as preventing type 1 diabetes-induced heart diseases.47

To elucidate the cardioprotective function of the NNCS in ischemic heart disease, Kakinuma et al.42 generated a heart-specific ChAT transgenic (ChAT-tg) mouse model that overexpresses ChAT in the heart to increase ACh synthesis. The findings revealed that cardiomyocyte-derived ACh plays an evident role in regulating myocardial energy metabolism through the activation of myocardial glucose utilization and angiogenesis in the infarcted area. Additionally, after 14 days, ChAT-tg mice exhibited increased resistance to MI and a higher survival rate compared to wild-type mice. This could be linked to the fact that cardiomyocyte-derived ACh activates hypoxia-inducible factor (HIF)-1α, a non-hypoxic mechanism, and efficiently prevents energy depletion in the heart.48

Moreover, cardiomyocyte-derived ACh increases cellular ATP levels. By monitoring ATP levels in real time, Oikawa et al.49 demonstrated that insulin growth factor (IGF)-1R and Glut-1 protein expressions were upregulated together with an increase of ACh-derived cardiomyocytes, leading to a rise in glucose uptake and utilization. This mechanism preserves cellular ATP levels during oxidative stress and suppresses ROS production.14 Therefore, overexpression of cardiomyocyte ChAT activates cardiac ACh-HIF-1α cascade and improves cell survival after myocardial I/R. Moreover, Kakinuma et al.42 found that upregulation of cardiomyocyte ChAT activates the cardiac ACh-HIF-1α cascade to improve cells in ChAT-tg myocardial I/R mice. Hence, loss of cardiac ACh-HIF-1α transcriptional pathway leads to cardiac dysfunction, which could be due to the synergistic effect of hypovascularity, calcium mishandling, and decreased myocardial energy.14

While the increase of sympathetic activity and norepinephrine is associated with arrhythmogenesis, cardiotoxicity, and impaired parasympathetic function, no link has been established between cardiomyocyte-derived ACh and cardiac norepinephrine levels.8 Consequently, the specific molecular mechanisms by which cardiomyocyte-derived ACh influences the cardiac cholinergic system remain unknown, underscoring the need for additional research. For instance, Kakinuma et al.35 suggested that cardiomyocytes increase the transcriptional activity of the ChAT gene through mAChRs and ChAT protein expression to increase ACh levels in the cholinergic system. Furthermore, studies have shown that the NNCS enhances vagus nerve activity by increasing the release of nitric oxide from cardiomyocytes, contributing to beneficial cardiac effects42,44 as well as extracardiac effect.50 Heart-specific ChAT-tg mice play a protective role in the central nervous system via the activation of the vagus nerve.44 This pathway is important in the regulation of the inflammatory response in the blood-brain barrier (BBB), as well as in the response to restraint stress, less depressive-like and anxiety-like behaviors, and anti-convulsive effects.44,50 Therefore, it is crucial to conduct further investigations to fully understand the true clinical potential of targeting the cardiac NNCS and its effects on peripheral organs. Future research should also focus on determining the optimal strategies for enhancing NNCS-derived ACh levels in the heart.

Cardioprotective roles of ACh via mAChRs and nAChRs

Impairments in ACh signaling from both neuronal and NNCS sources can result in cellular death, heart dysfunction, and suppression of anti-inflammatory pathways, mediated by mAChRs and nAChRs.51,52 Stimulation of mAChRs, which are G protein-coupled receptors, leads to a decrease in heart rate and reduced cardiac conductivity.53,54 mAChRs regulate ventricular function both directly by counteracting β-adrenergic stimulation and indirectly by inhibiting L-type calcium channels.55,56 nAChRs are cholinergic ligand-gated ion channels permeable to Na+, K+, and Ca2+10 and have a central role in the cholinergic anti-inflammatory pathway by maintaining immune homeostasis through the activation and differentiation of immune T cells and reducing pro-inflammatory cytokines.57 Moreover, the alpha 7 nicotinic ACh receptor subunit (α7nAChR) regulates blood flow and cardiac hemodynamics24 and enhances ACh release.58,59 While mAChRs and nAChRs trigger distinct signaling cascades across various cell types, they operate synergistically. Targeting both mAChRs and nAChRs through VNS or cholinesterase inhibitors improves left ventricular systolic function, prevents progressive left ventricular enlargement, and modulates the inflammatory response.52,60 The following sub-sections outline the cardioprotective effects of ACh in mitigating CVD through actions on mAChRs and nAChRs.

mAChRs

Type 2 muscarinic ACh receptors (M2AChRs) are the most commonly present receptor in the mammalian heart that activates several cardioprotective signaling pathways.61 Previous studies have shown that elevated ACh secretion in an injured heart promotes cardiomyocyte proliferation, suppresses ROS production, and prevents heart injury exacerbation via M2AChR.62,63,64,65 Activation of M2AChR also reduces mitochondrial oxidative damage in a DOX-induced rat model. This effect is mediated by Synapsin I, leading to heightened mitochondrial dynamics, while concurrently mitigating sympathetic activity and diminishing cardiac cell death, and necroptosis.16,66 ACh prevents cell apoptosis by inhibiting the action of angiotensin II (Ang II) and inhibits ROS production as well as cardiac hypertrophy by the activation of sirtuin 3/AMP-activated protein kinase (SIRT3-AMPK) signaling.67,68,69 ACh also prevents the progression of HF and cardiac remodeling through its inhibition of Ang II, improving survival rates in HF animal models, including mice, rats, and canines.9,39,70,71 Furthermore, ACh has the ability to activate superoxide dismutase, a crucial ROS-detoxifying enzyme in mitochondria and cytoplasm, which suppresses ROS production and protects against oxidative stress in I/R.72,73

Several studies have indicated that an increase in ACh levels activates cell survival mechanisms in the heart against I/R.74 ACh protects cardiomyocytes from ischemia through the transcription factor HIF-1α and downstream gene expression for cell survival. However, further studies need to be performed to fully identify these signaling pathways.75,76 Additionally, type 3 muscarinic ACh receptor (M3AChR) is found abundantly in cardiac fibroblast and plays a critical role in fibroblast proliferation. The activation of M3AChR during cardiac fibrosis leads to the inhibition of the mitogen-activated protein kinase (MAPK) signaling pathway, including p38MAPK and ERK1/2 associated with reduced collagen production and cardiac fibrosis.77

nAChRs

In the injured heart, ACh also binds to α7nAChR on various cell types, including cardiomyocytes, monocytes, macrophages, endothelial cells, and others involved in immune responses,10 thereby regulating systemic inflammatory responses in CVD patients.78 ACh inhibits the production of inflammatory cytokines such as tumor necrosis factor (TNF), interleukin (IL)-6, IL-1β, and IL-18, which are responsible for activating T cells.4,21,66,79,80 Additionally, ACh stimulates macrophages through paracrine signaling, resulting in a reduction in the release of pro-inflammatory cytokines, the uptake of oxidized LDL, and the buildup of cholesterol within macrophages.10,81

Through α7nAChR, ACh attenuates endothelial dysfunction and promotes vasodilation, improving blood flow to the injured heart.66 Li et al.81 showed that vascular injury in α7nAChR knockout mice led to vascular remodeling, arterial inflammation, and chemokines induction and increased oxidative vascular stress. Activation of α7nAChR can enhance tissue repair as well as reduce cardiac fibrosis damage.10,82 As cardiac fibrosis originates from endothelial cells through a process known as endothelial-to-mesenchymal transition,83 α7nAChR has the ability to significantly inhibit IL-1β-induced endothelial-to-mesenchymal transition, nuclear factor κB, and the induction of autophagy leading to the attenuation of cardiac fibrosis.13,76

In addition, ACh plays a significant role in cardiac angiogenesis via α7nAChR during cardiac hypertrophy and MI. Elevating ACh levels in MI mice enhances angiogenesis through vascular endothelial growth factor, leading to increased coronary arterial wall thickness and tube formation.68,84 Moreover, α7nAChR activation also plays a critical role in attenuating ROS by promoting mitochondrial fusion via upregulation of mitofusins (1–2) and thus inhibiting DOX-induced autophagy.16

The cardioprotective function of ACh is intricate, involving various downstream pathways mediated by mAChRs and nAChRs to prevent cell death and avert cardiac dysfunction in the injured human heart. Thus, further research is required to identify and evaluate therapeutic approaches aimed at increasing ACh levels and enhancing the activation of mAChRs and nAChRs without adverse effects.

Challenges and constraints to translate current strategies to clinical studies and alternative approaches

ACh has exhibited protective effects in various in vivo animal myocardial damage models. However, these benefits have been poorly translated into clinical trials. The primary challenge in translating ACh’s attributes to clinical trials is its rapid hydrolysis in the presence of cholinesterase and the widespread distribution of ACh receptors throughout the body. Moreover, in 1985, Shepherd and Vanhoutte85 found that ACh can detect coronary artery spasms (CADs). The current method for identifying CAD in patients is through intracoronary injection of ACh (ACh-provocation test). This technique is highly sensitive and specific for detecting various types of CAD, including epicardial coronary spasm, microvascular spasm, microvascular dysfunction, and coronary stenosis.86,87 Abnormal vascular responses to ACh, such as ischemic electrocardiogram changes, may be a consequence of endothelial dysfunction and hyperconstriction of vascular smooth muscle. The ACh-provocation test holds potential for tailoring treatment for CAD patients, as it is considered safe with irreversible non-fatal complications. However, it is crucial to note that injecting large doses of ACh (>100 μg) into the right coronary artery of CAD patients may lead to bradycardia lasting up to 45 min88,89

Several methods are commonly employed to elevate ACh levels in the neuronal cholinergic system, such as VNS via implanted stimulators or electrical stimulation and vagal efferent/afferent stimulation. Additionally, ACh levels can be increased in both the neuronal cholinergic system and NNCS through pharmacological interventions, including cholinesterase inhibitors. This section discusses current pre-clinical and clinical studies aimed at elevating ACh levels using VNS and cholinesterase inhibitors, examining their limitations and constraints, including the invasiveness of VNS and the adverse drug reactions (ADRs) associated with cholinesterase inhibitors. Furthermore, we explore potential alternative strategies to enhance ACh levels in the heart, including stem cell therapy, gene therapy, microRNA (miRNA) therapy, and the use of nanoparticles, highlighting the need for more targeted and less invasive approaches.

VNS

VNS is frequently used to elevate myocardial ACh levels within the neuronal cholinergic system, suggesting its potential as a therapeutic strategy to restore the autonomic balance and its anti-inflammatory effect.90 Numerous studies have demonstrated that VNS reduces infarct size, improves ventricular function, attenuates ROS production, and decreases ventricular fibrillation in I/R animal models,74,75,91 in hypotension and HF models,92 as well for a DOX-induced rat model93,94 through mAChRs and nAChRs. Uitterdijk et al.95 demonstrated that stimulating the vagus nerve in an ischemic swine model 5 min before reperfusion and continuing for 15 min post-reperfusion resulted in a significant reduction in infarct size. This intervention also led to a decrease in macrophages and neutrophils within the infarct area and mitigation of the no-reflow phenomenon through nAChRs.96,97 VNS exhibits protective effects against cardiomyocyte necrosis and microvascular obstruction, which could prevent reperfusion injury through both muscarinic and nicotinic pathways.65,98 Furthermore, Li et al.99 demonstrated that 6 weeks of VNS in HF mice prevented long-term remodeling and improved overall survival.

Despite the evident promise of VNS as a therapeutic strategy against I/R, Buchholz et al.23 showed that continuous VNS for 10 min before ischemia significantly increased the infarct size in a rabbit MI heart model. This opposite effect to what is reported earlier could be due to differences in VNS protocols and model species.100 Moreover, implanting electrodes to stimulate VNS is invasive, and the optimal electrical dosage remains uncertain.101 For instance, Sun et al.102 initially employed an electrical voltage of 10 Hz for 0.5 ms, which was subsequently fine-tuned to achieve a 10% reduction in heart rate in rats. This approach significantly constrained infarct size through the mAChRs pathway, mitigating cardiac dysfunction via the nAChRs pathway and extending their survival. While Shao et al.103 used a pulse frequency of 4 Hz and an intensity of 6 V to stimulate both right and left vagus nerves, ameliorating the myocardial function in rats by decreasing TNF-α level and arrhythmia score and increasing the expression of α7nAChR. Xue et al.104 used electrical voltage from 2 to 4 V to achieve a 10% decrease in the baseline heart rate. This method regulated metabolic homeostasis, modulated mitochondrial function and endoplasmic reticulum stress, and prevented myocardial necrosis and contractile dysfunction during MI in rats. This indicates that the effectiveness of VNS is significantly influenced by factors such as the electrical voltage pulses, stimulation duration, timing, and electrode positioning. These findings underscore the importance of carefully considering these parameters in pre-clinical trials to aim at safeguarding the myocardium against cardiac injury.

Among existing clinical trials, the first pilot study of VNS using CardioFit implantable system showed that VNS may improve quality of life and left ventricle function in chronic HF patients.105 However, large cohort clinical studies have shown mixed results.106 For instance, the INOVATE-HF clinical trial evaluated the impact of VNS in patients with HF, involving 390 individuals who received implants. Within 90 days, 46 complications occurred in 37 patients, and, after 16 months, VNS failed to demonstrate efficacy in reducing the mortality rate or HF-related events. Furthermore, it did not induce reverse remodeling or increase the left ventricle ejection fraction in this cohort.107 The ANTHEM-HF study investigated the impact of continuous cyclic stimulation on both the left and right vagus nerves in HF patients. One patient passed away 3 days after experiencing an embolic stroke during implantation while, in the remaining 59 patients, the devices were successfully implanted. At the six-month mark, the patients showed improvements in left ventricular ejection fraction, left ventricular end-systolic diameter, time-domain of heart rate variability, and high-sensitivity C-reactive protein levels. These findings indicate potential autonomic and anti-inflammatory effects of the treatment.108 Hence, it is crucial to acknowledge that VNS is an invasive procedure, and uncertainties persist regarding its safety and potential effects on the human heart.

Despite the fact that VNS is Food and Drug Administration approved for pharmaco-resistant depression, epilepsy, and stroke rehabilitation, the device implantation involves perioperative risks. Potential adverse effects include bradyarrhythmias, development of peritracheal hematoma, dyspnea, and respiratory complications.109,110 Furthermore, the establishment of an appropriate protocol for VNS in ischemic and HF patients remains unresolved, necessitating optimal techniques, and future studies are needed to discern the impact of long-term VNS on acute and chronic myocardial damage.3 Given the invasive nature of VNS and the perioperative risks associated with device implantation, alternative methods to modulate the cholinergic system must be considered. For instance, the application of transcutaneous VNS (tVNS) could provide the best clinical outcome and overcome surgical VNS limitations.111 The tVNS device is placed on either the anterior wall of the outer ear canal (tragus) or the cymba conchae, and it is inexpensive, low risk, and easy to administer. For instance, Choudhary et al.101 demonstrated that tVNS improves cardiac function and reduces MI area in rats. A 6-months clinical study from Stavrakis et al.112 demonstrated that the tVNS device reduces atrial fibrillation burden and TNF-α level and suppressed inflammation in patients with paroxysmal atrial fibrillation. However, there is a relative paucity of literature surrounding tVNS operation, functionality, and therapeutic effects.113 Future research is needed to identify the most efficient and safest approaches to enhance ACh levels in the heart and reduce side effects to the patients.

Cholinesterase inhibitors

A non-invasive pharmacological treatment could serve as a potential alternative to chronic VNS therapy, offering a means to target both the neuronal cholinergic system and NNCS. Donepezil, rivastigmine, pyridostigmine, and galantamine are reversible noncompetitive cholinesterase inhibitors. Donepezil is commonly used to prevent progressive neuronal damage,114,115 improve cognitive function, and delay the progression of Alzheimer’s disease116 and vascular dementia.117,118 Clinical trials and meta-analyses suggest that cholinesterase inhibitors, particularly donepezil, may be beneficial in combating CVD due to their anti-inflammatory properties and their ability to increase ACh levels in the heart, as observed in Alzheimer’s disease and dementia patients with CVD.119,120,121 Ongnok et al.115 reported that the administration of donepezil significantly mitigates brain pathologies caused by cardiac I/R. This treatment led to increase of BBB junction proteins expression, reduced brain inflammation and oxidative stress, improved mitochondrial function and dynamics, and alleviated amyloid-β accumulation and microglial activation. Furthermore, the cohort study by Nordström et al.122 indicated that the use of cholinesterase inhibitors was associated with a 35% reduced risk of MI and death in 7,073 individuals diagnosed with Alzheimer’s disease. However, the study was observational, and the patients had no prior history of CVD. Additionally, healthier patients received higher doses of cholinesterase inhibitors, which was more effective than the standard dose.123 Another cohort study found that dementia patients receiving cholinesterase inhibitors have a significantly lower risk of acute coronary syndrome. Consequently, donepezil may protect endothelial cells and improve cardiac vagal activity.120

Donepezil has demonstrated favorable cardioprotective effects in animal models against DOX-induced cardiotoxicity,16,66 MI,124 I/R,125 and HF.17 Additionally, Kakinuma et al. demonstrated that donepezil acts as an amplifier of NNCS activity by enhancing ACh synthesis through upregulating ChAT promoter activity in cardiomyocytes126 and cholinergic nerve cells.35 This could indicate that donepezil increases mAChRs and nAChRs activity by preventing ACh degradation and providing cardioprotective effects against CVD. Despite the impact of cholinesterase inhibitors on CVD, the benefit-to-harm ratio remains a crucial issue for clinical trials and adverse effects of cholinesterase inhibitors are significant. An analysis by Kröger et al.127 showed that the ADRs are neuropsychiatric (31.4%), gastrointestinal (15.9%), and cardiovascular (11.7%) disorders found in 18,955 reports (out of 43,753 ADRs). Cardiovascular disorders include a significant increase in the risk of bradycardia,128 hypotension,129,130 cardiac arrhythmia,131,132 and syncope.133 While a recent meta-analysis study found no association between donepezil and those cardiovascular disorders,134 donepezil still leads to ADRs such as tiredness, panic, sweating, diarrhea, vomiting, muscle tension, speech difficulty, and involuntary tremors.135 Hence, further research is needed to clarify the protective effects and ADRs of cholinesterase inhibitors against CVD.

Alternative approaches to target the cholinergic system

Multiple pieces of evidence strongly support the cardioprotective effects of ACh against CVD. Nevertheless, therapeutic approaches to target the cholinergic system remain uncertain and limited, warranting further exploration and investigation. This section proposes alternative approaches for future research, including ACh receptor stimulation, stem cell therapy, gene therapy, miRNA therapy, and nanoparticle drug delivery (Figure 2). Stem cell therapy offers a promising avenue for replenishing cholinergic neurons and fostering the regeneration of new, functional cardiomyocytes in hearts damaged by disease or injury. This approach could enhance self-repair mechanisms and improve the functionality of the damaged heart.18 While replenishing cholinergic neurons through stem cells has not been extensively studied due to the complexity of the human nervous system, cardiac cell-based therapies, such as bone marrow stem cells, embryonic stem cells (ESCs), and induced pluripotent stem cells (IPSCs), have been explored for their potential to regenerate cardiomyocytes that synthesize ACh.136,137,138 For instance, the transplantation of bone marrow-derived mononuclear cells has been shown to significantly elevate left ventricular ejection fraction in patients with non-ischemic dilated cardiomyopathy and acute MI. However, it has not led to myocardial regeneration.136,139 Moreover, in large phase 2 randomized controlled trials, stem cell therapy yielded modest results, which could be due to the poor quality of transplanting stem cells.140,141 Additionally, there are concerns with ESCs and IPSCs, such as high survival rates potentially leading to teratoma formation.142,143 Despite these challenges, further exploration into stem cell therapy could lead to significant advancements in achieving cardiac regeneration and restoring cardiac function.Figure 2 Schematic illustration of therapeutic approaches to target and elevate ACh levels in the infarcted heart

(A) These include vagal/vagus nerve stimulation to produce and secrete ACh.

(B and C) The other approach is through cholinesterase inhibitors to attenuate the degradation of ACh and prolong ACh effect in the extracellular space. Donepezil can simultaneously inhibit cholinesterase enzymes and increase ChAT expression.

(D and E) An alternative approach would be the use of stem cell therapies to either repopulate cholinergic neurons or replace damaged cardiomyocytes respectively.

(F) A fourth approach could include a positive allosteric modulator to stimulate mAChRs and nAChRs activity.

(G) Gene therapy could be a therapeutic strategy to increase the expression of the cholinergic genes such as ChAT, CHT1, and VAChT, which are responsible for ACh synthesis and secretion.

(H) Another possibility is targeting the cardiac miRNAs by diminishing levels of miRNAs that promote ACh degradation. ACh, acetylcholine; AChE, acetylcholinesterase; BChE, butyrylcholinesterase; ChAT, choline acetyltransferase; CHT1, high-affinity choline transporter; mAChRs, muscarinic acetylcholine receptors; nAChRs, nicotinic acetylcholine receptors; VAChT, vesicular acetylcholine transporter.

Another potential approach could be gene therapy, which aims to deliver the appropriate gene to be expressed and rescue the ischemic heart by increasing ACh synthesis or secretion pathways in cardiomyocytes. However, there are different types of vectors (non-viral and viral vectors) for gene delivery, and the selection of these vectors depends on the pathological condition of CVD patients. Different types of vectors lead to different durations of cardiac expression and transfection efficiency.144,145 Cholinergic markers, including ChAT42,46 or VAChT,45 could be considered new targets to increase ACh and restore the balance between the sympathetic and cholinergic systems in the ischemic heart. As mentioned earlier, ChAt-tg and VAChT-tg models provide cardioprotective effects against myocardial damage and ChAt-tg model also acts as a VNS. Moreover, increasing the overexpression of mAChRs and nAChRs could be another approach. Liu et al.146 showed that cardiac-specific M3-mAChR-tg mice significantly attenuated the hypertrophic response by reducing the expression of atrial natriuretic peptide and β-myosin heavy chain induced by Ang II. Nevertheless, the selection of the type of vector needs to be thoroughly considered and studied, as the main disadvantage of these vectors is that this technique could induce an inflammatory response.144 Therefore, additional research is required to find an effective in vivo delivery method, the duration of gene expression in the ischemic heart, and any potential toxicity effects in CVD patients.

miRNAs are essential regulators of gene expression. miRNA therapy could potentially target mRNA to inhibit translation or inhibit the degradation of ACh. For example, Oikawa et al.147 demonstrated that the expression of miR-345 was a regulator of the expression of ChAT mRNA in murine hearts. A synthetic inhibitor for miR-345 could be designed to increase ChAT protein expression and ACh synthesis.18 While Shaked et al.148 demonstrated that AChE-targeting miR-132 regulates inflammatory responses, Hanin and Soreq149 identified 116 and 128 microRNA (miRNA/miRs) that target the 3′-untranslated regions of BChE and AChE (47 for synaptic AChE-S variant and 81 for stress-inducible/readthrough AChE-R variant). However, the cholinesterase-targeting miR sequences show no relevance to most of the cholinesterases’ biological functions, suggesting that those sequences have yet to be explored. Hence, further validation is needed to confirm which miRNAs could directly target ChAT, VAChT, and cholinesterases. The effective delivery method and potential toxicity effects of miRNA therapy also remain unclear. More studies are required to find the ideal approach, determine the duration of its effects, and assess its toxicity effects on the heart and other parts of the body. To conclude, targeting the cardiac NNCS through gene or miRNA therapy seems to be the next step.

Furthermore, BChE is abundantly found in the human body,150 while AChE is present in various conducting tissues such as nerves, muscles, central and peripheral tissues, and motor and sensory fibers.22,151 BChE and AChE are present in the body anchored by collagen Q and proline-rich membrane anchors.152,153,154 BChE is also found as a soluble enzyme in the blood, and AChE subunits produce glycosylphosphatidylinositol-anchored dimers and are anchored to red blood cells.152,155,156,157 Under normal conditions, AChE has a higher affinity to hydrolyze ACh than BChE; BChE degrades ACh and carboxylic or phosphoric acid ester-containing compounds and plays important pharmacological and toxicological roles.158,159 For instance, increased BChE levels in monkeys160 and mice161 protected against the toxicity of nerve agents, such as organophosphorus poisoning and cocaine. While AChE inhibition in mice leads to BChE-mediated hydrolysis of ACh,158,162 inhibition of both BChE and AChE could have severe consequences for human health, including lethal intoxication.162,163 Recently, Dingová et al.164 showed that AChE anchored to the membrane of neurons and to the extracellular matrix hydrolyzes neuronal-derived ACh while BChE in the extracellular space hydrolyzes cardiomyocytes-derived ACh in mice hearts. Hence, future work should evaluate the distribution of cholinesterases and their role in the human heart prior to finding an optimal cholinesterase inhibitor to increase the ACh level. Therefore, delivering ACh at small doses and targeting the infarcted area using nanoparticles could be a promising therapeutic approach to increasing ACh levels in the heart. This strategy could potentially enhance the therapeutic effects while minimizing systemic side effects, offering a more precise and effective treatment for conditions requiring cholinergic modulation. Various nanocarriers such as dendrimers, nanometals, nanogels, liposomes, nano-emulsions, polymeric nanoparticles, and nanosuspensions have been studied to deliver drugs at small doses. Nanometal and liposomes nanocarriers have proven to be suitable to deliver ACh, a positively charged and hydrophilic molecule. Studies utilizing silver or gold nanoparticles, as well as chitosan nanoparticles, demonstrated neuroprotective effects against alleviating Alzheimer’s disease.165,166,167 However, these approaches are not currently being explored for CVD. Future research should investigate the potential of these nanocarriers for targeted ACh delivery in CVD, which could open new avenues for therapeutic interventions.

Conclusions and future directions

While inhibition of the cholinergic system leads to an increased heart rate, loss of cardiomyocytes,2 and increase of production of ROS,168 there is evidence that the physiological role of both the neuronal cholinergic system and NNCSs protects the heart against ischemic and chronic myocardial damage.3,14,19,48 For instance, the cholinergic system prevents cell apoptosis, inhibits ROS production and cardiac hypertrophy,61,62,63 and prevents the progression of HF and cardiac remodeling.9,38,64,65 Moreover, the cholinergic system provides beneficial immunomodulatory effects following heart tissue injury, such as stimulating macrophages, inhibiting the release of pro-inflammatory cytokines,10,75 attenuating endothelial dysfunction,60 and activating cardiac angiogenesis.68 However, the relationship between the neuronal cholinergic system and NNCS remains to be fully understood. Understanding the precise mechanisms and interactions between the neuronal cholinergic system and NNCS will also be vital for designing effective treatments.

Additionally, excessive production of ACh and its synthesis can lead to toxicity and bradycardia. Therefore, it is crucial to identify optimal methods for enhancing ACh levels in the heart. VNS and cholinesterase inhibitors are commonly employed to elevate ACh levels in the heart in pre-clinical and clinical studies. However, VNS is invasive, and cholinesterase inhibitors can cause ADRs. Hence, future research should focus on developing targeted and controlled delivery systems to increase ACh in cardiac tissues without causing adverse effects. This includes exploring the use of stem cell therapy, gene therapy, miRNA therapy, and nanoparticles to support and enhance the cholinergic system’s protective functions in the heart. In Figure 2, we also mention the potential use of positive allosteric modulators to selectively target specific subtypes of mAChRs and/or nAChRs, potentially increasing receptor affinity for ACh.169 However, current positive allosteric modulators lack specificity and often interact with multiple subtypes, leading to major ADRs such as increased heart rate and drowsiness due to the varied functions of each subtype and subunit of ACh receptors.170,171 Future research should focus on developing more targeted approaches for increasing ACh levels in the heart. This could involve the use of nanoparticle delivery systems or gene therapy to selectively enhance ACh production in cardiac tissue.

More importantly, it is crucial to understand the systemic interactions between the cardiac cholinergic system and other organs, as this will help elucidate the broader physiological impacts of modulating the cholinergic system in the heart. Moreover, long-term studies are necessary to evaluate the safety and efficacy of these alternatives approaches and the long-term effects and safety of enhancing ACh levels in the heart, including the chronic impacts on cardiac function and potential off-target effects. Exploring the potential benefits of combining cholinergic modulation with other therapeutic approaches, such as anti-inflammatory treatments or antioxidants, could provide a more comprehensive protective strategy against heart diseases. Addressing these future directions will help harness the full therapeutic potential of the cholinergic system for cardiovascular health and pave the way for innovative treatments for CVD.

Limitations of the study

In this review, we summarized the protective role of the cholinergic system, which produces and releases ACh during myocardial damage. We also highlighted the challenges and limitations of current approaches and suggested alternative approaches to elevate the ACh level in the injured heart. Although our review may not include all relevant studies due to limitations in the literature search, it offers a general overview. Certain findings, particularly ambiguous ones, might not be adequately introduced or discussed. We recommend more in-depth research and discussions to better clarify the roles of ACh in CVDs.

Acknowledgments

C.G. was supported by a University of Sydney Kick-Start grant, a Cardiothoracic Surgery Research Grant, UTS Seed Funding, 10.13039/501100022907 Catholic Archdiocese of Sydney Grant for Adult Stem Cell Research, Perpetual IMPACT, 10.13039/501100001208 Heart Research Australia grant and Heart Research Institute Fellowship . X.W. was supported by a National Heart Foundation Future Leader Fellowship and a Baker Fellowship. C.L.C.M. was supported by a NSW Waratah Scholarship.

Author contributions

C.L.C.M. and C.G. had the idea for the review. C.L.C.M. performed the literature search and drafted the original manuscript. X.W. and C.G. critically revised the work.

Declaration of interests

The authors declare no competing interests.
==== Refs
References

1 Cardiovascular Diseases (CVDs) https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) 2021
2 Mahmoud A.I. O'Meara C.C. Gemberling M. Zhao L. Bryant D.M. Zheng R. Gannon J.B. Cai L. Choi W.Y. Egnaczyk G.F. Nerves Regulate Cardiomyocyte Proliferation and Heart Regeneration Dev. Cell 34 2015 387 399 26256209
3 Intachai K. C Chattipakorn S. Chattipakorn N. Shinlapawittayatorn K. Revisiting the Cardioprotective Effects of Acetylcholine Receptor Activation against Myocardial Ischemia/Reperfusion Injury Int. J. Mol. Sci. 19 2018 2466 30134547
4 Rocha-Resende C. da Silva A.M. Prado M.A.M. Guatimosim S. Protective and anti-inflammatory effects of acetylcholine in the heart Am. J. Physiol. Cell Physiol. 320 2021 C155 C161 33264077
5 Ishise H. Asanoi H. Ishizaka S. Joho S. Kameyama T. Umeno K. Inoue H. Time course of sympathovagal imbalance and left ventricular dysfunction in conscious dogs with heart failure J. Appl. Physiol. 84 1998 1234 1241 9516189
6 Rovere M.T.L. Bigger J.T. Jr. Marcus F.I. Mortara A. Schwartz P.J. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction Lancet 351 1998 478 484 9482439
7 Lechat P. Hulot J.S. Escolano S. Mallet A. Leizorovicz A. Werhlen-Grandjean M. Pochmalicki G. Dargie H. Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial Circulation 103 2001 1428 1433 11245648
8 Guimarães D.A. Aquino N.S.S. Rocha-Resende C. Jesus I.C.G. Silva M.M. Scalzo S.A. Fonseca R.C. Durand M.T. Pereira V. Tezini G.C.S.V. Neuronal cholinergic signaling constrains norepinephrine activity in the heart Am. J. Physiol. Cell Physiol. 322 2022 C794 C801 35264016
9 An X. Cho H. Increased GIRK channel activity prevents arrhythmia in mice with heart failure by enhancing ventricular repolarization Sci. Rep. 13 2023 22479
10 Vieira-Alves I. Coimbra-Campos L.M.C. Sancho M. da Silva R.F. Cortes S.F. Lemos V.S. Role of the α7 Nicotinic Acetylcholine Receptor in the Pathophysiology of Atherosclerosis Front. Physiol. 11 2020 621769
11 Werner G.S. Wiegand V. Kreuzer H. Effect of acetylcholine on arterial and venous grafts and coronary arteries in patients with coronary artery disease Eur. Heart J. 11 1990 127 137 2311613
12 Bezerra O.C. França C.M. Rocha J.A. Neves G.A. Souza P.R.M. Teixeira Gomes M. Malfitano C. Loleiro T.C.A. Dourado P.M. Llesuy S. Cholinergic Stimulation Improves Oxidative Stress and Inflammation in Experimental Myocardial Infarction Sci. Rep. 7 2017 13687
13 Li X. Zhu X. Li B. Xia B. Tang H. Hu J. Ying R. Loss of α7nAChR enhances endothelial-to-mesenchymal transition after myocardial infarction via NF-κB activation Exp. Cell Res. 419 2022 113300
14 Braczko F. Reinders J. Lieder H.R. Heusch G. Kleinbongard P. Non-neuronal acetylcholine is causal for cardioprotection by hypoxic preconditioning in adult rat cardiomyocytes Eur. Heart J. 44 2023 ehad655-309
15 Calvillo L. Vanoli E. Andreoli E. Besana A. Omodeo E. Gnecchi M. Zerbi P. Vago G. Busca G. Schwartz P.J. Vagal stimulation, through its nicotinic action, limits infarct size and the inflammatory response to myocardial ischemia and reperfusion J. Cardiovasc. Pharmacol. 58 2011 500 507 21765369
16 Prathumsap N. Ongnok B. Khuanjing T. Arinno A. Maneechote C. Apaijai N. Chunchai T. Arunsak B. Shinlapawittayatorn K. Chattipakorn S.C. Chattipakorn N. Acetylcholine receptor agonists provide cardioprotection in doxorubicin-induced cardiotoxicity via modulating muscarinic M2 and α7 nicotinic receptor expression Transl. Res. 243 2022 33 51 34920165
17 Handa T. Katare R.G. Kakinuma Y. Arikawa M. Ando M. Sasaguri S. Yamasaki F. Sato T. Anti-Alzheimer's Drug, Donepezil, Markedly Improves Long-Term Survival After Chronic Heart Failure in Mice J. Card. Fail. 15 2009 805 811 19879468
18 Saw E.L. Kakinuma Y. Fronius M. Katare R. The non-neuronal cholinergic system in the heart: A comprehensive review J. Mol. Cell. Cardiol. 125 2018 129 139 30343172
19 Fujii T. Mashimo M. Moriwaki Y. Misawa H. Ono S. Horiguchi K. Kawashima K. Expression and Function of the Cholinergic System in Immune Cells Front. Immunol. 8 2017 1085
20 Fujii T. Mashimo M. Moriwaki Y. Misawa H. Ono S. Horiguchi K. Kawashima K. Physiological functions of the cholinergic system in immune cells J. Pharmacol. Sci. 134 2017 1 21 28552584
21 Borovikova L.V. Ivanova S. Nardi D. Zhang M. Yang H. Ombrellino M. Tracey K.J. Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation Auton. Neurosci. 85 2000 141 147 11189021
22 Koelle G.B. The histochemical localization of cholinesterases in the central nervous system of the rat J. Comp. Neurol. 100 1954 211 235 13130712
23 Buchholz B. Donato M. Perez V. Ivalde F.C. Höcht C. Buitrago E. Rodríguez M. Gelpi R.J. Preischemic efferent vagal stimulation increases the size of myocardial infarction in rabbits. Role of the sympathetic nervous system Int. J. Cardiol. 155 2012 490 491 22257691
24 Targosova K. Kucera M. Fazekas T. Kilianova Z. Stankovicova T. Hrabovska A. α7 nicotinic receptors play a role in regulation of cardiac hemodynamics J. Neurochem. 168 2024 414 427 37017608
25 Ojiakor O.A. Rylett R.J. Modulation of sodium-coupled choline transporter CHT function in health and disease Neurochem. Int. 140 2020 104810
26 Rocha-Resende C. Roy A. Resende R. Ladeira M.S. Lara A. de Morais Gomes E.R. Prado V.F. Gros R. Guatimosim C. Prado M.A.M. Guatimosim S. Non-neuronal cholinergic machinery present in cardiomyocytes offsets hypertrophic signals J. Mol. Cell. Cardiol. 53 2012 206 216 22587993
27 Cavey D. Vincent J.P. Làzdunski M. The muscarinic receptor of heart cell membranes Association with agonists, antagonists and antiarrhythmic agents FEBS Lett. 84 1977 110 114 590510
28 Corringer P.-J. Galzi J.L. Eiselé J.L. Bertrand S. Changeux J.P. Bertrand D. Identification of a new component of the agonist binding site of the nicotinic α7 homooligomeric receptor J. Biol. Chem. 270 1995 11749 11752 7744821
29 Devillers-Thiéry A. Galzi J.L. Eiselé J.L. Bertrand S. Bertrand D. Changeux J.P. Functional architecture of the nicotinic acetylcholine receptor: a prototype of ligand-gated ion channels J. Membr. Biol. 136 1993 97 112 7508983
30 Mesulam M.M. Guillozet A. Shaw P. Levey A. Duysen E.G. Lockridge O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine Neuroscience 110 2002 627 639 11934471
31 Kuhar M.J. Murrin L.C. Sodium-dependent, high affinity choline uptake J. Neurochem. 30 1978 15 21 340615
32 Tarnawski L. Shavva V.S. Kort E.J. Zhuge Z. Nilsson I. Gallina A.L. Martínez-Enguita D. Heller Sahlgren B. Weiland M. Caravaca A.S. Cholinergic regulation of vascular endothelial function by human ChAT+ T cells Proc. Natl. Acad. Sci. USA 120 2023 e2212476120
33 Eduardo C.-R.C. Alejandra T.I.G. Guadalupe D.R.K.J. Herminia V.R.G. Lenin P. Enrique B.V. Evandro B.M. Oscar B. Iván G.P.M. Modulation of the extraneuronal cholinergic system on main innate response leukocytes J. Neuroimmunol. 327 2019 22 35 30683425
34 Kakinuma Y. Non-neuronal cholinergic system in the heart influences its homeostasis and an extra-cardiac site, the blood-brain barrier Front. Cardiovasc. Med. 11 2024 1384637
35 Kakinuma Y. Akiyama T. Sato T. Cholinoceptive and cholinergic properties of cardiomyocytes involving an amplification mechanism for vagal efferent effects in sparsely innervated ventricular myocardium FEBS J. 276 2009 5111 5125 19674111
36 Rana O.R. Schauerte P. Kluttig R. Schröder J.W. Koenen R.R. Weber C. Nolte K.W. Weis J. Hoffmann R. Marx N. Saygili E. Acetylcholine as an age-dependent non-neuronal source in the heart Auton. Neurosci. 156 2010 82 89 20510655
37 Roy A. Fields W.C. Rocha-Resende C. Resende R.R. Guatimosim S. Prado V.F. Gros R. Prado M.A.M. Cardiomyocyte-secreted acetylcholine is required for maintenance of homeostasis in the heart FASEB J. 27 2013 5072 5082 24018063
38 Gavioli M. Lara A. Almeida P.W.M. Lima A.M. Damasceno D.D. Rocha-Resende C. Ladeira M. Resende R.R. Martinelli P.M. Melo M.B. Cholinergic signaling exerts protective effects in models of sympathetic hyperactivity-induced cardiac dysfunction PLoS One 9 2014 e100179 24992197
39 Lara A. Damasceno D.D. Pires R. Gros R. Gomes E.R. Gavioli M. Lima R.F. Guimarães D. Lima P. Bueno C.R. Jr. Dysautonomia due to reduced cholinergic neurotransmission causes cardiac remodeling and heart failure Mol. Cell Biol. 30 2010 1746 1756 20123977
40 Roy A. Dakroub M. Tezini G.C.S.V. Liu Y. Guatimosim S. Feng Q. Salgado H.C. Prado V.F. Prado M.A.M. Gros R. Cardiac acetylcholine inhibits ventricular remodeling and dysfunction under pathologic conditions FASEB J. 30 2016 688 701 26481308
41 Kakinuma Y. Akiyama T. Okazaki K. Arikawa M. Noguchi T. Sato T. A non-neuronal cardiac cholinergic system plays a protective role in myocardium salvage during ischemic insults PLoS One 7 2012 e50761
42 Kakinuma Y. Tsuda M. Okazaki K. Akiyama T. Arikawa M. Noguchi T. Sato T. Heart-specific overexpression of choline acetyltransferase gene protects murine heart against ischemia through hypoxia-inducible factor-1α-related defense mechanisms J. Am. Heart Assoc. 2 2013 e004887 23525439
43 Reardon C. Duncan G.S. Brüstle A. Brenner D. Tusche M.W. Olofsson P.S. Rosas-Ballina M. Tracey K.J. Mak T.W. Lymphocyte-derived ACh regulates local innate but not adaptive immunity Proc. Natl. Acad. Sci. USA 110 2013 1410 1415 23297238
44 Oikawa S. Kai Y. Tsuda M. Ohata H. Mano A. Mizoguchi N. Sugama S. Nemoto T. Suzuki K. Kurabayashi A. Non-neuronal cardiac cholinergic system influences CNS via the vagus nerve to acquire a stress-refractory propensity Clin. Sci. 130 2016 1913 1928
45 Rocha-Resende C. Weinheimer C. Bajpai G. Adamo L. Matkovich S.J. Schilling J. Barger P.M. Lavine K.J. Mann D.L. Immunomodulatory role of nonneuronal cholinergic signaling in myocardial injury JCI insight 5 2019 e128961 31162139
46 Saw E.L. Pearson J.T. Schwenke D.O. Munasinghe P.E. Tsuchimochi H. Rawal S. Coffey S. Davis P. Bunton R. Van Hout I. Activation of the cardiac non-neuronal cholinergic system prevents the development of diabetes-associated cardiovascular complications Cardiovasc. Diabetol. 20 2021 50 33618724
47 Munasinghe P.E. Saw E.L. Reily-Bell M. Tonkin D. Kakinuma Y. Fronius M. Katare R. Non-neuronal cholinergic system delays cardiac remodelling in type 1 diabetes Heliyon 9 2023 e17434
48 Braczko F. Reinders J. Lieder H. Heusch G. Kleinbongard P. The Non-Neuronal Cholinergic System is Causal for Cardioprotection by Hypoxic Preconditioning in Isolated Adult Rat Cardiomyocytes FASEB J. 327 2021 H70 H79
49 Oikawa S. Iketani M. Kakinuma Y. A non-neuronal cholinergic system regulates cellular ATP levels to maintain cell viability Cell. Physiol. Biochem. 34 2014 781 789 25170772
50 Oikawa S. Kai Y. Mano A. Sugama S. Mizoguchi N. Tsuda M. Muramoto K. Kakinuma Y. Potentiating a non-neuronal cardiac cholinergic system reinforces the functional integrity of the blood brain barrier associated with systemic anti-inflammatory responses Brain Behav. Immun. 81 2019 122 137 31176726
51 McAreavey D. Neilson J.M. Ewing D.J. Russell D.C. Cardiac parasympathetic activity during the early hours of acute myocardial infarction Br. Heart J. 62 1989 165 170 2789908
52 Khuanjing T. Palee S. Chattipakorn S.C. Chattipakorn N. The effects of acetylcholinesterase inhibitors on the heart in acute myocardial infarction and heart failure: From cells to patient reports Acta Physiol. 228 2020 e13396
53 LaCroix C. Freeling J. Giles A. Wess J. Li Y.F. Deficiency of M2 muscarinic acetylcholine receptors increases susceptibility of ventricular function to chronic adrenergic stress Am. J. Physiol. Heart Circ. Physiol. 294 2008 H810 H820 18055517
54 Tettelbaum H.A. Newton J.E.O. Gantt W.H. Cardiovascular responses to acetylcholine: Effects of pentobarbital and autonomic blocking agents Cond. Reflex Pavlovian J. Res. Therapy 6 1971 101 118
55 Hare J.M. Keaney J.F. Jr. Balligand J.L. Loscalzo J. Smith T.W. Colucci W.S. Role of nitric oxide in parasympathetic modulation of beta-adrenergic myocardial contractility in normal dogs J. Clin. Invest. 95 1995 360 366 7529262
56 Henning R.J. Khalil I.R. Levy M.N. Vagal stimulation attenuates sympathetic enhancement of left ventricular function Am. J. Physiol. 258 1990 H1470 H1475 2337181
57 Ren C. Tong Y.L. Li J.C. Lu Z.Q. Yao Y.M. The Protective Effect of Alpha 7 Nicotinic Acetylcholine Receptor Activation on Critical Illness and Its Mechanism Int. J. Biol. Sci. 13 2017 46 56 28123345
58 Petrov K.A. Proskurina S.E. Krejci E. Cholinesterases in Tripartite Neuromuscular Synapse Front. Mol. Neurosci. 14 2021 811220
59 Osipov A.V. Averin A.S. Shaykhutdinova E.R. Dyachenko I.A. Tsetlin V.I. Utkin Y.N. Muscarinic and nicotinic acetylcholine receptors in the regulation of the cardiovascular system Russ. J. Bioorg. Chem. 49 2023 3 22
60 Capilupi M.J. Kerath S.M. Becker L.B. Vagus Nerve Stimulation and the Cardiovascular System Cold Spring Harbor Perspect. Med. 10 2020 a034173
61 Fei Y.-D. Chen M. Guo S. Ueoka A. Chen Z. Rubart-von der Lohe M. Everett T.H. 4th Qu Z. Weiss J.N. Chen P.S. Simultaneous activation of the small conductance calcium-activated potassium current by acetylcholine and inhibition of sodium current by ajmaline cause J-wave syndrome in Langendorff-perfused rabbit ventricles Heart Rhythm 18 2021 98 108 32763429
62 Kakinuma Y. Ando M. Kuwabara M. Katare R.G. Okudela K. Kobayashi M. Sato T. Acetylcholine from vagal stimulation protects cardiomyocytes against ischemia and hypoxia involving additive non-hypoxic induction of HIF-1α FEBS Lett. 579 2005 2111 2118 15811327
63 Soeki T. Niki T. Uematsu E. Bando S. Matsuura T. Kusunose K. Ise T. Ueda Y. Tomita N. Yamaguchi K. Ghrelin protects the heart against ischemia-induced arrhythmias by preserving connexin-43 protein Heart Ves. 28 2013 795 801
64 Tsutsumi T. Ide T. Yamato M. Kudou W. Andou M. Hirooka Y. Utsumi H. Tsutsui H. Sunagawa K. Modulation of the myocardial redox state by vagal nerve stimulation after experimental myocardial infarction Cardiovasc. Res. 77 2008 713 721 18065771
65 Nuntaphum W. Pongkan W. Wongjaikam S. Thummasorn S. Tanajak P. Khamseekaew J. Intachai K. Chattipakorn S.C. Chattipakorn N. Shinlapawittayatorn K. Vagus nerve stimulation exerts cardioprotection against myocardial ischemia/reperfusion injury predominantly through its efferent vagal fibers Basic Res. Cardiol. 113 2018 22 29744667
66 Khuanjing T. Ongnok B. Maneechote C. Siri-Angkul N. Prathumsap N. Arinno A. Chunchai T. Arunsak B. Chattipakorn S.C. Chattipakorn N. Acetylcholinesterase inhibitor ameliorates doxorubicin-induced cardiotoxicity through reducing RIP1-mediated necroptosis Pharmacol. Res. 173 2021 105882
67 Liu J.-J. Li D.L. Zhou J. Sun L. Zhao M. Kong S.S. Wang Y.H. Yu X.J. Zhou J. Zang W.J. Acetylcholine prevents angiotensin II-induced oxidative stress and apoptosis in H9c2 cells Apoptosis 16 2011 94 103 20963497
68 Xu M. Xue R.Q. Lu Y. Yong S.Y. Wu Q. Cui Y.L. Zuo X.T. Yu X.J. Zhao M. Zang W.J. Choline ameliorates cardiac hypertrophy by regulating metabolic remodelling and UPRmt through SIRT3-AMPK pathway Cardiovasc. Res. 115 2019 530 545 30165480
69 Xue R.-Q. Zhao M. Wu Q. Yang S. Cui Y.L. Yu X.J. Liu J. Zang W.J. Regulation of mitochondrial cristae remodelling by acetylcholine alleviates palmitate-induced cardiomyocyte hypertrophy Free Radic. Biol. Med. 145 2019 103 117 31553938
70 Katare R.G. Ando M. Kakinuma Y. Arikawa M. Handa T. Yamasaki F. Sato T. Vagal nerve stimulation prevents reperfusion injury through inhibition of opening of mitochondrial permeability transition pore independent of the bradycardiac effect J. Thorac. Cardiovasc. Surg. 137 2009 223 231 19154929
71 Sun J. Lu Y. Huang Y. Wugeti N. Unilateral vagus nerve stimulation improves ventricular autonomic nerve distribution and functional imbalance in a canine heart failure model Int. J. Clin. Exp. Med. 8 2015 9334 9340 26309593
72 Wang Z. Zhao G. Zibrila A.I. Li Y. Liu J. Feng W. Acetylcholine ameliorated hypoxia-induced oxidative stress and apoptosis in trophoblast cells via p38 MAPK/NF-κB pathway Mol. Hum. Reprod. 27 2021 gaab045
73 Intachai K. Chattipakorn S.C. Chattipakorn N. Shinlapawittayatorn K. Acetylcholine exerts cytoprotection against hypoxia/reoxygenation-induced apoptosis, autophagy and mitochondrial impairment through both muscarinic and nicotinic receptors Apoptosis 27 2022 233 245 35092545
74 Shinlapawittayatorn K. Chinda K. Palee S. Surinkaew S. Kumfu S. Kumphune S. Chattipakorn S. KenKnight B.H. Chattipakorn N. Vagus nerve stimulation initiated late during ischemia, but not reperfusion, exerts cardioprotection via amelioration of cardiac mitochondrial dysfunction Heart Rhythm 11 2014 2278 2287 25093803
75 Zhang J. Yong Y. Li X. Hu Y. Wang J. Wang Y.Q. Song W. Chen W.T. Xie J. Chen X.M. Vagal modulation of high mobility group box-1 protein mediates electroacupuncture-induced cardioprotection in ischemia-reperfusion injury Sci. Rep. 5 2015 15503
76 Li Z. Li X. Zhu Y. Chen Q. Li B. Zhang F. Protective effects of acetylcholine on hypoxia-induced endothelial-to-mesenchymal transition in human cardiac microvascular endothelial cells Mol. Cell. Biochem. 473 2020 101 110 32602017
77 Zhao L. Chen T. Hang P. Li W. Guo J. Pan Y. Du J. Zheng Y. Du Z. Choline Attenuates Cardiac Fibrosis by Inhibiting p38MAPK Signaling Possibly by Acting on M3 Muscarinic Acetylcholine Receptor Front. Pharmacol. 10 2019 1386 31849653
78 Lampert R. Bremner J.D. Su S. Miller A. Lee F. Cheema F. Goldberg J. Vaccarino V. Decreased heart rate variability is associated with higher levels of inflammation in middle-aged men Am. Heart J. 156 2008 759.e1 759.e7
79 Borovikova L.V. Ivanova S. Zhang M. Yang H. Botchkina G.I. Watkins L.R. Wang H. Abumrad N. Eaton J.W. Tracey K.J. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin Nature 405 2000 458 462 10839541
80 Parrish W.R. Rosas-Ballina M. Gallowitsch-Puerta M. Ochani M. Ochani K. Yang L.H. Hudson L. Lin X. Patel N. Johnson S.M. Modulation of TNF release by choline requires alpha7 subunit nicotinic acetylcholine receptor-mediated signaling Mol. Med. 14 2008 567 574 18584048
81 Li D.-J. Fu H. Tong J. Li Y.H. Qu L.F. Wang P. Shen F.M. Cholinergic anti-inflammatory pathway inhibits neointimal hyperplasia by suppressing inflammation and oxidative stress Redox Biol. 15 2018 22 33 29197233
82 Huston J.M. Tracey K.J. The pulse of inflammation: heart rate variability, the cholinergic anti-inflammatory pathway and implications for therapy J. Intern. Med. 269 2011 45 53 21158977
83 Zeisberg E.M. Tarnavski O. Zeisberg M. Dorfman A.L. McMullen J.R. Gustafsson E. Chandraker A. Yuan X. Pu W.T. Roberts A.B. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis Nat. Med. 13 2007 952 961 17660828
84 Hao C. Huang Z.H. Song S.W. Shi Y.Q. Cheng X.W. Murohara T. Lu W. Su D.F. Duan J.L. Arterial Baroreflex Dysfunction Impairs Ischemia-Induced Angiogenesis J. Am. Heart Assoc. 3 2014 e000804 24820655
85 Shepherd J.T. Vanhoutte P.M. Spasm of the Coronary Arteries: Causes and Consequences (the Scientist's Viewpoint) Mayo Clin. Proc. 60 1985 33 46 2856944
86 Suzuki S. Kaikita K. Yamamoto E. Jinnouchi H. Tsujita K. Role of acetylcholine spasm provocation test as a pathophysiological assessment in nonobstructive coronary artery disease Cardiovasc. Interv. Ther. 36 2021 39 51 33108592
87 Ishii M. Kaikita K. Sato K. Tanaka T. Sugamura K. Sakamoto K. Izumiya Y. Yamamoto E. Tsujita K. Yamamuro M. Acetylcholine-Provoked Coronary Spasm at Site of Significant Organic Stenosis Predicts Poor Prognosis in Patients With Coronary Vasospastic Angina J. Am. Coll. Cardiol. 66 2015 1105 1115 26337988
88 Isogai T. Yasunaga H. Matsui H. Tanaka H. Ueda T. Horiguchi H. Fushimi K. Serious cardiac complications in coronary spasm provocation tests using acetylcholine or ergonovine: analysis of 21 512 patients from the diagnosis procedure combination database in Japan Clin. Cardiol. 38 2015 171 177 25693967
89 Erickson S.R. Yousuf M.J. Hypotension and bradycardia possibly associated with intraocular injection of acetylcholine DICP 25 1991 1178 1180 1763531
90 Hadaya J. Ardell J.L. Autonomic modulation for cardiovascular disease Front. Physiol. 11 2020 617459
91 Buchholz B. Donato M. Perez V. Deutsch A.C.R. Höcht C. Del Mauro J.S. Rodríguez M. Gelpi R.J. Changes in the loading conditions induced by vagal stimulation modify the myocardial infarct size through sympathetic-parasympathetic interactions Pflugers Arch. 467 2015 1509 1522 25127674
92 Cavalcante G.L. Brognara F. Oliveira L.V.d.C. Lataro R.M. Durand M.d.T. de Oliveira A.P. da Nóbrega A.C.L. Salgado H.C. Sabino J.P.J. Benefits of pharmacological and electrical cholinergic stimulation in hypertension and heart failure Acta Physiol. 232 2021 e13663
93 Guo F. Wang Y. Wang J. Liu Z. Lai Y. Zhou Z. Liu Z. Zhou Y. Xu X. Li Z. Choline Protects the Heart from Doxorubicin-Induced Cardiotoxicity through Vagal Activation and Nrf2/HO-1 Pathway Oxid. Med. Cell. Longev. 2022 2022 4740931
94 Siripakkaphant C. Ongnok B. Prathumsap N. Khuanjing T. Chunchai T. Arunsak B. Pantiya P. Chattipakorn N. Chattipakorn S.C. Vagus Nerve Stimulation Provides Neuroprotection Against Doxorubicin-induced Chemobrain Via Activations of Both Muscarinic and Nicotinic Acetylcholine Receptors Alzheimer's Dementia 19 2023 e073548
95 Uitterdijk A. Yetgin T. te Lintel Hekkert M. Sneep S. Krabbendam-Peters I. van Beusekom H.M.M. Fischer T.M. Cornelussen R.N. Manintveld O.C. Merkus D. Duncker D.J. Vagal nerve stimulation started just prior to reperfusion limits infarct size and no-reflow Basic Res. Cardiol. 110 2015 508 26306761
96 Galasso G. Schiekofer S. D'Anna C. Gioia G.D. Piccolo R. Niglio T. Rosa R.D. Strisciuglio T. Cirillo P. Piscione F. Trimarco B. No-reflow phenomenon: pathophysiology, diagnosis, prevention, and treatment. A review of the current literature and future perspectives Angiology 65 2014 180 189 23362304
97 Schwartz B.G. Kloner R.A. Coronary no reflow J. Mol. Cell. Cardiol. 52 2012 873 882 21712046
98 Zhao M. He X. Bi X.Y. Yu X.J. Gil Wier W. Zang W.J. Vagal stimulation triggers peripheral vascular protection through the cholinergic anti-inflammatory pathway in a rat model of myocardial ischemia/reperfusion Basic Res. Cardiol. 108 2013 345 23519622
99 Li M. Zheng C. Sato T. Kawada T. Sugimachi M. Sunagawa K. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats Circulation 109 2004 120 124 14662714
100 Liu Chung Ming C. Sesperez K. Ben-Sefer E. Arpon D. McGrath K. McClements L. Gentile C. Considerations to Model Heart Disease in Women with Preeclampsia and Cardiovascular Disease Cells 10 2021 899 33919808
101 Choudhary R.C. Ahmed U. Shoaib M. Alper E. Rehman A. Kim J. Shinozaki K. Volpe B.T. Chavan S. Zanos S. Threshold adjusted vagus nerve stimulation after asphyxial cardiac arrest results in neuroprotection and improved survival Bioelectron. Med. 8 2022 10 35854394
102 Sun P. Wang J. Zhao S. Yang Z. Tang Z. Ravindra N. Bradley J. Ornato J.P. Peberdy M.A. Tang W. Improved Outcomes of Cardiopulmonary Resuscitation in Rats Treated With Vagus Nerve Stimulation and Its Potential Mechanism Shock 49 2018 698 703 28800036
103 Shao W.J. Shu T.T. Xu S. Liang L.C. Grange J.M.L. Zhou Y.R. Huang H. Cai Y. Zhang Q. Sun P. Left-sided vagus nerve stimulation improves cardiopulmonary resuscitation outcomes in rats as effectively as right-sided vagus nerve stimulation World J. Emerg. Med. 12 2021 309 316 34512829
104 Xue R.-Q. Sun L. Yu X.J. Li D.L. Zang W.J. Vagal nerve stimulation improves mitochondrial dynamics via an M3 receptor/CaMKKβ/AMPK pathway in isoproterenol-induced myocardial ischaemia J. Cell Mol. Med. 21 2017 58 71 27491814
105 De Ferrari G.M. Crijns H.J.G.M. Borggrefe M. Milasinovic G. Smid J. Zabel M. Gavazzi A. Sanzo A. Dennert R. Kuschyk J. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure Eur. Heart J. 32 2011 847 855 21030409
106 Zafeiropoulos S. Ahmed U. Bikou A. Mughrabi I.T. Stavrakis S. Zanos S. Vagus nerve stimulation for cardiovascular diseases: Is there light at the end of the tunnel? Trends Cardiovasc. Med. 34 2024 327 337 37506989
107 Gold M.R. Van Veldhuisen D.J. Hauptman P.J. Borggrefe M. Kubo S.H. Lieberman R.A. Milasinovic G. Berman B.J. Djordjevic S. Neelagaru S. Vagus Nerve Stimulation for the Treatment of Heart Failure J. Am. Coll. Cardiol. 68 2016 149 158 27058909
108 Premchand R.K. Sharma K. Mittal S. Monteiro R. Dixit S. Libbus I. DiCarlo L.A. Ardell J.L. Rector T.S. Amurthur B. Autonomic Regulation Therapy via Left or Right Cervical Vagus Nerve Stimulation in Patients With Chronic Heart Failure: Results of the ANTHEM-HF Trial J. Card. Fail. 20 2014 808 816 25187002
109 Dawson J. Liu C.Y. Francisco G.E. Cramer S.C. Wolf S.L. Dixit A. Alexander J. Ali R. Brown B.L. Feng W. Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial Lancet 397 2021 1545 1553 33894832
110 Yap J.Y.Y. Keatch C. Lambert E. Woods W. Stoddart P.R. Kameneva T. Critical Review of Transcutaneous Vagus Nerve Stimulation: Challenges for Translation to Clinical Practice Front. Neurosci. 14 2020 284 32410932
111 Elamin A.B.A. Forsat K. Senok S.S. Goswami N. Vagus Nerve Stimulation and Its Cardioprotective Abilities: A Systematic Review J. Clin. Med. 12 2023 1717
112 Stavrakis S. Stoner J.A. Humphrey M.B. Morris L. Filiberti A. Reynolds J.C. Elkholey K. Javed I. Twidale N. Riha P. TREAT AF (Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation) JACC. Clin. Electrophysiol. 6 2020 282 291 32192678
113 Butt M.F. Albusoda A. Farmer A.D. Aziz Q. The anatomical basis for transcutaneous auricular vagus nerve stimulation J. Anat. 236 2020 588 611 31742681
114 Wiendl H. Elger C. Förstl H. Hartung H.P. Oertel W. Reichmann H. Schwab S. Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage ("Neuroprotection") Neurotherapeutics 12 2015 449 454 25773662
115 Ongnok B. Khuanjing T. Chunchai T. Kerdphoo S. Jaiwongkam T. Chattipakorn N. Chattipakorn S.C. Donepezil provides neuroprotective effects against brain injury and Alzheimer's pathology under conditions of cardiac ischemia/reperfusion injury Biochim. Biophys. Acta, Mol. Basis Dis. 1867 2021 165975
116 Birks J.S. Harvey R.J. Donepezil for dementia due to Alzheimer's disease Cochrane Database Syst. Rev. 6 2018 Cd001190 29923184
117 Battle C.E. Abdul-Rahim A.H. Shenkin S.D. Hewitt J. Quinn T.J. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis Cochrane Database Syst. Rev. 2 2021 CD013306 33704781
118 Jian W.-X. Zhang Z. Zhan J.H. Chu S.F. Peng Y. Zhao M. Wang Q. Chen N.H. Donepezil attenuates vascular dementia in rats through increasing BDNF induced by reducing HDAC6 nuclear translocation Acta Pharmacol. Sin. 41 2020 588 598 31913348
119 Kazmierski J. Messini-Zachou C. Gkioka M. Tsolaki M. The Impact of a Long-Term Rivastigmine and Donepezil Treatment on All-Cause Mortality in Patients With Alzheimer’s Disease Am. J. Alzheimers Dis. Other Demen. 33 2018 385 393 29742912
120 Wu P.-H. Lin Y.T. Hsu P.C. Yang Y.H. Lin T.H. Huang C.T. Impact of acetylcholinesterase inhibitors on the occurrence of acute coronary syndrome in patients with dementia Sci. Rep. 5 2015 15451
121 Isik A.T. Soysal P. Stubbs B. Solmi M. Basso C. Maggi S. Schofield P. Veronese N. Mueller C. Cardiovascular Outcomes of Cholinesterase Inhibitors in Individuals with Dementia: A Meta-Analysis and Systematic Review J. Am. Geriatr. Soc. 66 2018 1805 1811 29851022
122 Nordström P. Religa D. Wimo A. Winblad B. Eriksdotter M. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease Eur. Heart J. 34 2013 2585 2591 23735859
123 Wang H. Zong Y. Han Y. Zhao J. Liu H. Liu Y. Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer’s disease: a systematic review and meta-analysis Expert Opin. Drug Saf. 21 2022 407 415 35099343
124 Li M. Zheng C. Kawada T. Uemura K. Yokota S. Matsushita H. Saku K. Donepezil attenuates progression of cardiovascular remodeling and improves prognosis in spontaneously hypertensive rats with chronic myocardial infarction Hypertens. Res. 47 2024 1298 1308 38485776
125 Khuanjing T. Palee S. Kerdphoo S. Jaiwongkam T. Anomasiri A. Chattipakorn S.C. Chattipakorn N. Donepezil attenuated cardiac ischemia/reperfusion injury through balancing mitochondrial dynamics, mitophagy, and autophagy Transl. Res. 230 2021 82 97 33137536
126 Kakinuma Y. Furihata M. Akiyama T. Arikawa M. Handa T. Katare R.G. Sato T. Donepezil, an acetylcholinesterase inhibitor against Alzheimer's dementia, promotes angiogenesis in an ischemic hindlimb model J. Mol. Cell. Cardiol. 48 2010 680 693 19962381
127 Kröger E. Mouls M. Wilchesky M. Berkers M. Carmichael P.H. van Marum R. Souverein P. Egberts T. Laroche M.L. Adverse Drug Reactions Reported With Cholinesterase Inhibitors:An Analysis of 16 Years of Individual Case Safety Reports From VigiBase Ann. Pharmacother. 49 2015 1197 1206 26324356
128 Morris R. Luboff H. Jose R.P. Eckhoff K. Bu K. Pham M. Rohlsen-Neal D. Cheng F. Bradycardia Due to Donepezil in Adults: Systematic Analysis of FDA Adverse Event Reporting System J. Alzheimers Dis. 81 2021 297 307 33780370
129 Bordier P. Garrigue S. Lanusse S. Margaine J. Robert F. Gencel L. Lafitte A. Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer’s disease CNS Drugs 20 2006 411 417 16696580
130 Pu Z. Xu W. Lin Y. Shen J. Sun Y. Donepezil decreases heart rate in elderly patients with Alzheimer’s disease Int. J. Clin. Pharmacol. Ther. 57 2019 94 100 30378536
131 Suleyman T. Tevfik P. Abdulkadir G. Ozlem S. Complete atrioventricular block and ventricular tachyarrhythmia associated with donepezil Emerg. Med. J. 23 2006 641 642 16858101
132 Hadano Y. Ogawa H. Wakeyama T. Iwami T. Kimura M. Mochizuki M. Akashi S. Miyazaki Y. Nakashima T. Shimizu A. Donepezil-induced torsades de pointes without QT prolongation J. Cardiol. Cases 8 2013 e69 e71 30546746
133 Malik B.H. Hamid P. Khan S. Gupta D. Islam M. Correlation between donepezil and QTc prolongation and torsades de pointes: a very rare phenomenon Cureus 11 2019 e6451
134 Nham T. Garcia M.C. Tsang K.J. Silva J.M. Schneider T. Deng J. Lohit S. Mbuagbaw L. Holbrook A. Proarrhythmic major adverse cardiac events with donepezil: A systematic review with meta-analysis J. Am. Geriatrics Soc 1 2024 1
135 Li H.-C. Luo K.X. Wang J.S. Wang Q.X. Extrapyramidal side effect of donepezil hydrochloride in an elderly patient: a case report Medicine 99 2020 e19443
136 Wen Y. Ding J. Zhang B. Gao Q. Bone marrow-derived mononuclear cell therapy for nonischaemic dilated cardiomyopathy—A meta-analysis Eur. J. Clin. Invest. 48 2018 e12894
137 Nasseri B.A. Ebell W. Dandel M. Kukucka M. Gebker R. Doltra A. Knosalla C. Choi Y.H. Hetzer R. Stamm C. Autologous CD133+ bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: the Cardio133 trial Eur. Heart J. 35 2014 1263 1274 24497345
138 Liu Chung Ming C. Ben-Sefer E. Gentile C. Stem Cell-Based 3D Bioprinting for Cardiovascular Tissue Regeneration Advanced Technologies in Cardiovascular Bioengineering 2022 Springer 281 312
139 Delewi R. Andriessen A. Tijssen J.G. Zijlstra F. Piek J.J. Hirsch A. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a meta-analysis of randomised controlled clinical trials Heart 99 2012 225 22875736
140 Nollet E. Hoymans V.Y. Van Craenenbroeck A.H. Vrints C.J. Van Craenenbroeck E.M. Improving stem cell therapy in cardiovascular diseases: the potential role of microRNA Am. J. Physiol. Heart Circ. Physiol. 311 2016 H207 H218 27208159
141 Afzal M.R. Samanta A. Shah Z.I. Jeevanantham V. Abdel-Latif A. Zuba-Surma E.K. Dawn B. Adult bone marrow cell therapy for ischemic heart disease: evidence and insights from randomized controlled trials Circ. Res. 117 2015 558 575 26160853
142 Nasser M.I. Qi X. Zhu S. He Y. Zhao M. Guo H. Zhu P. Current situation and future of stem cells in cardiovascular medicine Biomed. Pharmaco. 132 2020 110813
143 An Y. Sekinaka T. Tando Y. Okamura D. Tanaka K. Ito-Matsuoka Y. Takehara A. Yaegashi N. Matsui Y. Derivation of pluripotent stem cells from nascent undifferentiated teratoma Dev. Biol. 446 2019 43 55 30529251
144 Rincon M.Y. VandenDriessche T. Chuah M.K. Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation Cardiovasc. Res. 108 2015 4 20 26239654
145 Xu M. Song J. Targeted therapy in cardiovascular disease: A precision therapy era Front. Pharmacol. 12 2021 623674
146 Liu Y. Wang S. Wang C. Song H. Han H. Hang P. Jiang Y. Wei L. Huo R. Sun L. Upregulation of M3 muscarinic receptor inhibits cardiac hypertrophy induced by angiotensin II J. Transl. Med. 11 2013 209 24028210
147 Oikawa S. Kai Y. Mano A. Ohata H. Nemoto T. Kakinuma Y. Various regulatory modes for circadian rhythmicity and sexual dimorphism in the non-neuronal cardiac cholinergic system J. Cardiovasc. Transl. Res. 10 2017 411 422 28497301
148 Shaked I. Meerson A. Wolf Y. Avni R. Greenberg D. Gilboa-Geffen A. Soreq H. MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase Immunity 31 2009 965 973 20005135
149 Hanin G. Soreq H. Cholinesterase-Targeting microRNAs Identified in silico Affect Specific Biological Processes Front. Mol. Neurosci. 4 2011 28
150 Manoharan I. Boopathy R. Darvesh S. Lockridge O. A medical health report on individuals with silent butyrylcholinesterase in the Vysya community of India Clin. Chim. Acta 378 2007 128 135 17182021
151 Pytel E. Bukowska B. Koter-Michalak M. Olszewska-Banaszczyk M. Gorzelak-Pabiś P. Broncel M. Effect of intensive lipid-lowering therapies on cholinesterase activity in patients with coronary artery disease Pharmacol. Rep. 69 2017 150 155 27923158
152 Massoulié J. The Origin of the Molecular Diversity and Functional Anchoring of Cholinesterases Neurosignals 11 2002 130 143 12138250
153 Perrier A.L. Massoulié J. Krejci E. PRiMA: the membrane anchor of acetylcholinesterase in the brain Neuron 33 2002 275 285 11804574
154 Kilianova Z. Ciznarova N. Szmicsekova K. Slobodova L. Hrabovska A. Expression of cholinesterases and their anchoring proteins in rat heart Can. J. Physiol. Pharmacol. 98 2020 473 476 32017610
155 Prall Y.G. Gambhir K.K. Ampy F.R. Acetylcholinesterase: An enzymatic marker of human red blood cell aging Life Sci. 63 1998 177 184 9698047
156 Altamirano C.V. Lockridge O. Association of tetramers of human butyrylcholinesterase is mediated by conserved aromatic residues of the carboxy terminus Chem. Biol. Interact. 119 1999 53 60 10421438
157 Liang D. Blouet J.P. Borrega F. Bon S. Massoulié J. Respective roles of the catalytic domains and C-terminal tail peptides in the oligomerization and secretory trafficking of human acetylcholinesterase and butyrylcholinesterase FEBS J. 276 2009 94 108 19019080
158 Li B. Duysen E.G. Carlson M. Lockridge O. The butyrylcholinesterase knockout mouse as a model for human butyrylcholinesterase deficiency J. Pharmacol. Exp. Ther. 324 2008 1146 1154 18056867
159 Lockridge O. Masson P. Pesticides and susceptible populations: people with butyrylcholinesterase genetic variants may be at risk Neurotoxicology 21 2000 113 126 10794391
160 Broomfield C.A. Maxwell D.M. Solana R.P. Castro C.A. Finger A.V. Lenz D.E. Protection by butyrylcholinesterase against organophosphorus poisoning in nonhuman primates J. Pharmacol. Exp. Ther. 259 1991 633 638 1941611
161 Murthy V. Gao Y. Geng L. LeBrasseur N.K. White T.A. Parks R.J. Brimijoin S. Physiologic and metabolic safety of butyrylcholinesterase gene therapy in mice Vaccine 32 2014 4155 4162 24892251
162 Hartmann J. Kiewert C. Duysen E.G. Lockridge O. Greig N.H. Klein J. Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity J. Neurochem. 100 2007 1421 1429 17212694
163 Chatonnet A. Lockridge O. Comparison of butyrylcholinesterase and acetylcholinesterase Biochem. J. 260 1989 625 634 2669736
164 Dingová D. Kucera M. Hodbod T. Fischmeister R. Krejci E. Hrabovska A.P. Cardiac acetylcholinesterase and butyrylcholinesterase have distinct localization and function bioRxiv 1 2024 2024 10.1101/2024.05.29.596481
165 Sankar M. Karthikeyan R. Vigneshkumar S. Synthesis and Characterization of Chitosan Acetylcholine Nanoparticles for Neural Disorders Associated with Cancer Treatment J. Inorg. Organomet. Polym. 33 2023 2465 2484
166 Abdelwahab G.M. Mira A. Cheng Y.B. Abdelaziz T.A. Lahloub M.F.I. Khalil A.T. Acetylcholine esterase inhibitory activity of green synthesized nanosilver by naphthopyrones isolated from marine-derived Aspergillus niger PLoS One 16 2021 e0257071 34506550
167 Alami A.E. Lagarde F. Huo Q. Zheng T. Baitoul M. Daniel P. Acetylcholine and acetylcholinesterase inhibitors detection using gold nanoparticles coupled with dynamic light scattering Sensors Int. 1 2020 100007
168 Roy A. Guatimosim S. Prado V.F. Gros R. Prado M.A.M. Cholinergic Activity as a New Target in Diseases of the Heart Mol. Med. 20 2015 527 537 25222914
169 Foster D.J. Conn P.J. Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders Neuron 94 2017 431 446 28472649
170 Andersson K.-E. Antimuscarinics for treatment of overactive bladder Lancet Neurol. 3 2004 46 53 14693111
171 Naicker P. Anoopkumar-Dukie S. Grant G.D. Kavanagh J.J. Anticholinergic activity in the nervous system: Consequences for visuomotor function Physiol. Behav. 170 2017 6 11 27965143
